|
SHORT STATURE, AUDITORY CANAL ATRESIA, MANDIBULAR HYPOPLASIA, SKELETAL ABNORMALITIES
|
0.630 |
GeneticVariation
|
disease |
BEFREE |
This confirms that SAMS is a human malformation syndrome resulting from GSC mutations.
|
24290375 |
2013 |
|
SHORT STATURE, AUDITORY CANAL ATRESIA, MANDIBULAR HYPOPLASIA, SKELETAL ABNORMALITIES
|
0.630 |
GermlineCausalMutation
|
disease |
ORPHANET |
This confirms that SAMS is a human malformation syndrome resulting from GSC mutations.
|
24290375 |
2013 |
|
SHORT STATURE, AUDITORY CANAL ATRESIA, MANDIBULAR HYPOPLASIA, SKELETAL ABNORMALITIES
|
0.630 |
Biomarker
|
disease |
BEFREE |
The acronym SAMS (Short stature, Auditory canal atresia, Mandibular hypoplasia, and Skeletal abnormalities) was suggested to describe the main manifestations in this syndrome.
|
12116210 |
2002 |
|
SHORT STATURE, AUDITORY CANAL ATRESIA, MANDIBULAR HYPOPLASIA, SKELETAL ABNORMALITIES
|
0.630 |
Biomarker
|
disease |
BEFREE |
SAMS: provisionally unique multiple congenital anomalies syndrome consisting of short stature, auditory canal atresia, mandibular hypoplasia, and skeletal abnormalities.
|
9475592 |
1998 |
|
SHORT STATURE, AUDITORY CANAL ATRESIA, MANDIBULAR HYPOPLASIA, SKELETAL ABNORMALITIES
|
0.630 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Nasal and pharyngeal abnormalities caused by the mouse goosecoid gene mutation.
|
9144415 |
1997 |
|
SHORT STATURE, AUDITORY CANAL ATRESIA, MANDIBULAR HYPOPLASIA, SKELETAL ABNORMALITIES
|
0.630 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Congenital small ears
|
0.310 |
Biomarker
|
disease |
BEFREE |
The Gsc gene and the BMP5 maternal peptide gene may act as the predisposing genes of microtia.
|
19935299 |
2009 |
|
Congenital small ears
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Nasal and pharyngeal abnormalities caused by the mouse goosecoid gene mutation.
|
9144415 |
1997 |
|
Craniofacial Abnormalities
|
0.300 |
Biomarker
|
group |
CTD_human |
Goosecoid acts cell autonomously in mesenchyme-derived tissues during craniofacial development.
|
10433910 |
1999 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compounds 9 and 12 showed significant cytotoxic potency against GSC-18# (IC<sub>50</sub> =1.351 and 4.439 μg ml<sup>-1</sup> , respectively) and GSC-3# (IC<sub>50</sub> =10.88 and 6.348 μg ml<sup>-1</sup> , respectively) glioma stem cells, while compound 12 was also slightly less potent against GSC-12# (IC<sub>50</sub> =13.45 μg ml<sup>-1</sup> ) glioma stem cell growth.
|
30801931 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Live-cell imaging, in vitro PDT, and in vivo studies were performed to elucidate the effect lapatinib had on PDT for a variety of glioma cell lines and as well as GSC-30 neurospheres in vivo.
|
31847378 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we determined whether leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), known as a stem cell marker for colon cancer and gastric cancer, can serve as a novel GSC marker involved in EMT and a therapeutic target in glioma.
|
30208924 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The antitumor activity of the compounds against the glioma stem cells (GSC-3#, GSC-12#, GSC-18#) were investigated by phenotypic screening and MTS assays.
|
30195875 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies showed Demethoxycurcumin (DMC) has stronger anti-glioma and anti-GSCs effects both in vitro and in vivo.
|
29575236 |
2018 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
A t<i>G</i>LI1 activation signature (tGAS) correlated with glioma grade, tumor angiogenesis, and poor overall survival, and GBMs with high tGAS were enriched with mesenchymal GBM/GSC gene signatures.
|
29463580 |
2018 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to find new GB/GSC marker candidates that would be cell surface proteins (CSP), we have performed meta-analysis of genome-scale mRNA expression data from three data repositories (GEO, ArrayExpress and GLIOMASdb).
|
29734672 |
2018 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Glioma stem cells (GSCs) make up highly tumorigenic subpopulations within gliomas, and aberrant expression of GSC genes is a major underlying cause of glioma pathogenesis and treatment failure.
|
28666797 |
2017 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also observed that MET associated with TMZ was able to reduce the expression of glioma stem cells (GSC) marker CD90 particularly in T98G cells but not that of CD133.
|
29348889 |
2017 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study discovers a previously unrecognized role of AEG-1 in GSC biology and supports the significance of this gene as a potential therapeutic target for glioblastoma multiforme.
|
27903708 |
2017 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy.
|
28419967 |
2017 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry and flow cytometry analysis of 12 tumor samples obtained from patients with high grade gliomas revealed that a considerable population (2-19%) of cells in all malignant gliomas expressed IL-17RA, with remarkable co-expression of the glioma stem cell (GSC) markers CD133, Nestin, and Sox2.
|
26755664 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glioma stem cells (GSCs) significantly contribute to GBM progression and post-treatment tumor relapse, therefore serving as a key therapeutic target; however, GSCs are resistant to conventional radiation therapy.
|
26354413 |
2015 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glioma stem cells (GSCs) significantly contribute to GBM progression and post-treatment tumor relapse, therefore serving as a key therapeutic target; however, GSCs are resistant to conventional radiation therapy.
|
26354413 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hESC methylator-negative phenotype has demonstrated poor survival and upregulation of glioma stem cell (GSC) markers, and is enriched in one of the previously defined transcriptomic phenotypes-the mesenchymal phenotype.
|
24601786 |
2014 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, basic GBM and GSC genetics and proteomics studies combined with strategies to discover GSC-targeting agents could lead to novel treatments that significantly improve patient survival and quality of life.
|
24657832 |
2014 |